Companies: 10,795·Total market cap: $144.5T
Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc.

ELVNNASDAQHealthcare● Active
$33.68
$-1.03(-2.97%)
Market Cap$2.1B
P/E Ratio—
52W High$48.53
52W Low$14.785
SEC Filings

Enliven Therapeutics, Inc. (ELVN) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001672619 · ELVN · NASDAQ · as of Jun 8, 2026

Filing snapshot

751
Total Filings
144
Latest Form
2026-06-05
Most Recent
2020
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001672619 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-03
Fiscal Year End
Mar 3, 2026
Accession No.
0001193125-26-088232
Primary Document
elvn-20251231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001672619 · Accession 0001193125-26-088232

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-07
View 10-Q on SEC
8-KCurrent Report
8-K
2026-05-07Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
10-QQuarterly Report
10-Q
2026-05-07
View
8-KCurrent Report
8-K
2026-05-07
View
ARSARS
ARS
2026-04-27
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-27
View
DEF 14AProxy Statement
DEF 14A
2026-04-27
View
PRE 14APRE 14A
PRE 14A
2026-04-15
View
S-8Employee Stock Plan Registration
S-8
2026-03-03
View
10-KAnnual Report
10-K
2026-03-03
View
8-KCurrent Report
8-K
2026-03-03
View
Showing 1–15 of 286 filingsForm 4 / 144 hidden· 751 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001672619  |  Exchange: NASDAQ · Healthcare

Enliven Therapeutics, Inc. (NASDAQ: ELVN) has submitted 751 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2020. As a Healthcare sector company with CIK 0001672619, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Enliven Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Enliven Therapeutics, Inc. 10-K was filed on 2026-03-03 for fiscal year ending 2026. Historical ELVN 10-K annual reports are available from 2016 through 2026.

Investors researching Enliven Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
DNTH SEC Filings →RLAY SEC Filings →SNDX SEC Filings →ATAI SEC Filings →INBX SEC Filings →IMTX SEC Filings →NKTR SEC Filings →PGEN SEC Filings →
→ ELVN Financials→ ELVN Earnings→ ELVN Insider Trades

Frequently Asked Questions

ELVN SEC Filings · 8 questions

Enliven Therapeutics, Inc. (ELVN) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 751 filings and access original documents at no cost. Enliven Therapeutics, Inc.'s CIK is 0001672619.

ELVN SEC filingsEnliven Therapeutics, Inc. SEC documentsfind ELVN 10-K